CSS
FATE icon

Cubist Systematic Strategies’s Fate Therapeutics FATE Stock Holding History

Cubist Systematic Strategies’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-111,512
Closed -$125K – 3167
2025
Q2 		$125K Buy
+111,512
New +$130K ﹤0.01% 2682
2025
Q1 		– Sell
-7,776
Closed -$12.8K – 3050
2024
Q4 		$12.8K Buy
+7,776
New +$19.6K ﹤0.01% 2853
2024
Q1 		– Sell
-214,345
Closed -$802K – 3890
2023
Q4 		$802K Buy
214,345
+179,543
+516% +$424K 0.01% 2212
2023
Q3 		$73.8K Sell
34,802
-420,135
-92% -$1.39M ﹤0.01% 2978
2023
Q2 		$2.17M Sell
454,937
-188,182
-29% -$1.04M 0.01% 1424
2023
Q1 		$3.67M Buy
643,119
+70,570
+12% +$426K 0.02% 1177
2022
Q4 		$5.78M Buy
572,549
+313,923
+121% +$5.9M 0.03% 886
2022
Q3 		$5.8M Sell
258,626
-108,436
-30% -$3.13M 0.03% 931
2022
Q2 		$9.1M Buy
367,062
+350,056
+2,058% +$9.66M 0.06% 507
2022
Q1 		$659K Buy
17,006
+6,410
+60% +$248K 0.01% 2354
2021
Q4 		$620K Sell
10,596
-70,438
-87% -$3.99M 0.01% 2289
2021
Q3 		$4.8M Buy
81,034
+62,238
+331% +$4.88M 0.06% 486
2021
Q2 		$1.63M Sell
18,796
-24,283
-56% -$1.96M 0.02% 1229
2021
Q1 		$3.55M Sell
43,079
-28,281
-40% -$2.71M 0.05% 640
2020
Q4 		$6.49M Sell
71,360
-15,112
-17% -$938K 0.09% 320
2020
Q3 		$3.46M Buy
86,472
+86,372
+86,372% +$3.02M 0.05% 584
2020
Q2 		$3K Buy
+100
New +$2.98K ﹤0.01% 2356
2020
Q1 		– Sell
-44,217
Closed -$865K – 2241
2019
Q4 		$865K Buy
44,217
+44,212
+884,240% +$702K 0.02% 1248
2019
Q3 		$0 Sell
5
-4,943
-100% -$94.8K ﹤0.01% 2278
2019
Q2 		$100K Buy
4,948
+2,086
+73% +$37.6K ﹤0.01% 2233
2019
Q1 		$50K Sell
2,862
-18,403
-87% -$290K ﹤0.01% 2103
2018
Q4 		$273K Buy
+21,265
New +$296K 0.01% 1348

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wilshire Advisors Santa Monica, California $10.3M AUM 79.91% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Cubist Systematic Strategies's FATE Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of Fate Therapeutics (FATE) in Q3 2025, closing a stake of 111,512 shares — an estimated $125K sold.

Cubist Systematic Strategies first reported a position in FATE in Q4 2018 and held it in 22 quarters. The position peaked at $9.1M in Q2 2022. 143 funds tracked by Wall St. Rank hold FATE as of Q3 2025.

  • Cubist Systematic Strategies reported no remaining Fate Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 111,512 Fate Therapeutics shares in Q3 2025, an estimated $125K.
  • Cubist Systematic Strategies first reported a position in Fate Therapeutics in Q4 2018 and held it in 22 quarters.
  • Cubist Systematic Strategies's Fate Therapeutics position peaked at $9.1M in Q2 2022.
  • 143 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.